[go: up one dir, main page]

MX381228B - Inhibidores de la interacción de menina-leucemia de linaje mixto. - Google Patents

Inhibidores de la interacción de menina-leucemia de linaje mixto.

Info

Publication number
MX381228B
MX381228B MX2018015252A MX2018015252A MX381228B MX 381228 B MX381228 B MX 381228B MX 2018015252 A MX2018015252 A MX 2018015252A MX 2018015252 A MX2018015252 A MX 2018015252A MX 381228 B MX381228 B MX 381228B
Authority
MX
Mexico
Prior art keywords
interaction
inhibitors
menina
mixed lineage
lineage leukemia
Prior art date
Application number
MX2018015252A
Other languages
English (en)
Other versions
MX2018015252A (es
Inventor
Andrew Marcus
Angel Morales-Ramos
Chengguo Dong
David A Claremon
Jing Yuan
Lanqi Jia
Lawrence Wayne Dillard
Linghang Zhuang
Salvacion Cacatian
Shankar Venkatraman
Stephan D Parent
Stephen D Lotesta
Suresh B Singh
Travis L Houston
Yajun Zheng
Yi Fan
Original Assignee
Vitae Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Llc filed Critical Vitae Pharmaceuticals Llc
Publication of MX2018015252A publication Critical patent/MX2018015252A/es
Publication of MX381228B publication Critical patent/MX381228B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invencion se refiere a inhibidores de la interaccion de menina con MLL y proteinas de fusion de MLL, composiciones farmaceuticas que contienen los mismos, y su uso en el tratamiento de cancer y otras enfermedades mediadas por la interaccion de menina-MLL.
MX2018015252A 2016-06-10 2017-06-08 Inhibidores de la interacción de menina-leucemia de linaje mixto. MX381228B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348496P 2016-06-10 2016-06-10
PCT/US2017/036506 WO2017214367A1 (en) 2016-06-10 2017-06-08 Inhibitors of the menin-mll interaction

Publications (2)

Publication Number Publication Date
MX2018015252A MX2018015252A (es) 2019-04-25
MX381228B true MX381228B (es) 2025-03-12

Family

ID=59325631

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018015252A MX381228B (es) 2016-06-10 2017-06-08 Inhibidores de la interacción de menina-leucemia de linaje mixto.
MX2023002982A MX2023002982A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2021003939A MX2021003939A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023002982A MX2023002982A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2021003939A MX2021003939A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.

Country Status (21)

Country Link
US (3) US10683302B2 (es)
EP (2) EP3805215A1 (es)
JP (3) JP7007302B2 (es)
KR (2) KR20220123727A (es)
CN (1) CN109743875B (es)
AU (3) AU2017278950B2 (es)
BR (1) BR122024002146A2 (es)
CA (1) CA3024180A1 (es)
CY (1) CY1124834T1 (es)
DK (1) DK3468966T3 (es)
ES (1) ES2831084T3 (es)
HR (1) HRP20201771T1 (es)
HU (1) HUE051451T2 (es)
IL (3) IL298381A (es)
LT (1) LT3468966T (es)
MX (3) MX381228B (es)
PL (1) PL3468966T3 (es)
PT (1) PT3468966T (es)
SI (1) SI3468966T1 (es)
WO (1) WO2017214367A1 (es)
ZA (1) ZA201900150B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
SG11201807834WA (en) 2016-03-16 2018-10-30 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
MX2018013433A (es) 2016-05-02 2019-07-18 Univ Michigan Regents Piperidinas como inhibidores de menina.
DK3468966T3 (da) 2016-06-10 2020-11-09 Vitae Pharmaceuticals Llc Inhibitorer af menin-mll-interaktionen
JP7033141B2 (ja) 2016-09-14 2022-03-09 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用の縮合二環式阻害剤
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のアゼパン阻害剤
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
KR20190133224A (ko) 2017-03-31 2019-12-02 더 리젠츠 오브 더 유니버시티 오브 미시간 공유 메닌 억제제로서의 피페리딘
EP3611164B1 (en) * 2017-04-10 2024-08-28 Mitsui Chemicals Crop & Life Solutions, Inc. Pyridone compound, and agricultural and horticultural fungicide having this as active component
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) * 2017-09-20 2021-09-08 Kura Oncology, Inc. MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
MA51337A (fr) * 2017-12-20 2020-10-28 Janssen Pharmaceutica Nv Inhibiteurs spiro exo-aza de l'interaction ménine-mll
JP7239562B2 (ja) 2018-03-30 2023-03-14 住友ファーマ株式会社 光学活性な架橋型環状２級アミン誘導体
JP6671574B1 (ja) 2018-08-27 2020-03-25 大日本住友製薬株式会社 光学活性なアザビシクロ環誘導体
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
CN111285875B (zh) * 2018-12-06 2023-02-03 苏州信诺维医药科技股份有限公司 一种杂环化合物、其应用及含其的药物组合物
BR112021007421A2 (pt) 2018-12-06 2021-08-03 Daiichi Sankyo Company, Limited derivado de cicloalcano-1,3-diamina
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
TW202043205A (zh) * 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
EP4041389A1 (en) 2019-10-09 2022-08-17 Novartis AG 2-azaspiro[3.4]octane derivatives as m4 agonists
AR120169A1 (es) * 2019-10-09 2022-02-02 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
KR20220118500A (ko) * 2019-12-19 2022-08-25 얀센 파마슈티카 엔.브이. 치환 직쇄 스피로 유도체
JP7454520B2 (ja) 2020-02-26 2024-03-22 住友ファーマ株式会社 光学活性なアザビシクロ環誘導体からなる医薬
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
JP2023522166A (ja) * 2020-04-07 2023-05-29 シンダックス ファーマシューティカルズ， インコーポレイテッド メニン阻害剤とｃｙｐ３ａ４阻害剤との組合せ、およびその使用方法
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
RU2752079C1 (ru) * 2020-12-01 2021-07-22 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Е)-(6-(2-гидроксифенил)-2-иминио-4,7,8-триоксо-1,3-дифенил-1,3,6-триазаспиро[4.4]нонан-9-илиден)(4-метоксифенил)метаноат, обладающий противомикробной активностью, и способ его получения
MX2023013176A (es) 2021-05-08 2023-12-01 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
PH12023552974A1 (en) * 2021-05-11 2024-03-11 Janssen Pharmaceutica Nv Combination therapies
CA3214861A1 (en) * 2021-05-11 2022-11-17 Nikki DASKALAKIS Combination therapies
CA3213074A1 (en) * 2021-05-14 2022-11-17 Salvacion Cacatian Inhibitors of the menin-mll interaction
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253309A1 (zh) * 2021-06-03 2022-12-08 首药控股(北京)股份有限公司 取代的杂环化合物及其应用
JP2024521902A (ja) 2021-06-03 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
WO2022257047A1 (en) * 2021-06-09 2022-12-15 Acerand Therapeutics (Hong Kong) Limited Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof
KR20240021808A (ko) 2021-06-17 2024-02-19 얀센 파마슈티카 엔브이 암과 같은 질환의 치료를 위한 (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드 베실레이트 염
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
TW202313004A (zh) 2021-08-20 2023-04-01 美商拜歐米富士恩股份有限公司 Ｍｅｎｉｎ－ｍｌｌ相互作用之不可逆抑制劑的結晶形式
CN113769098B (zh) * 2021-09-22 2022-09-30 中国医学科学院肿瘤医院深圳医院 MLL-menin抑制剂组合物在制备抗肝癌药物中的应用
WO2023098876A1 (en) * 2021-12-03 2023-06-08 Bionova Pharmaceuticals (Shanghai) Limited Carbonyl substituted diazaspiro compounds and its use
EP4458823A1 (en) * 2021-12-31 2024-11-06 Hitgen Inc. Menin inhibitor and use thereof
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
WO2024046457A1 (en) * 2022-09-02 2024-03-07 Hutchmed Limited Triazine compounds and uses thereof
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024140798A1 (zh) * 2022-12-30 2024-07-04 成都先导药物开发股份有限公司 Menin抑制剂及其用途
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
WO2024213101A1 (zh) * 2023-04-13 2024-10-17 首药控股(北京)股份有限公司 取代的杂环化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
SG194219A1 (en) 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
EP2968342B1 (en) * 2013-03-13 2018-10-03 The Regents of the University of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US20170119769A1 (en) * 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN108779116A (zh) 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
DK3468966T3 (da) 2016-06-10 2020-11-09 Vitae Pharmaceuticals Llc Inhibitorer af menin-mll-interaktionen

Also Published As

Publication number Publication date
CN109743875A (zh) 2019-05-10
AU2021258089A1 (en) 2021-11-25
BR122024002146A2 (pt) 2024-03-05
RU2019100040A3 (es) 2020-07-15
CN109743875B (zh) 2022-04-29
CY1124834T1 (el) 2022-07-22
JP2019517548A (ja) 2019-06-24
EP3468966B1 (en) 2020-08-05
IL263586B (en) 2021-06-30
HUE051451T2 (hu) 2021-03-01
EP3805215A1 (en) 2021-04-14
WO2017214367A1 (en) 2017-12-14
ES2831084T3 (es) 2021-06-07
US10683302B2 (en) 2020-06-16
JP7007302B2 (ja) 2022-01-24
PT3468966T (pt) 2020-11-10
JP2022058514A (ja) 2022-04-12
KR20190017012A (ko) 2019-02-19
PL3468966T3 (pl) 2021-04-06
JP2024045176A (ja) 2024-04-02
BR112018075260A2 (pt) 2019-03-12
KR102436430B1 (ko) 2022-08-24
IL283267B2 (en) 2023-04-01
AU2017278950A1 (en) 2019-01-03
JP7461390B2 (ja) 2024-04-03
DK3468966T3 (da) 2020-11-09
US20210053974A1 (en) 2021-02-25
AU2017278950B2 (en) 2021-07-29
AU2021258089B2 (en) 2024-01-25
AU2024202700A1 (en) 2024-05-16
ZA201900150B (en) 2023-04-26
IL298381A (en) 2023-01-01
LT3468966T (lt) 2021-02-25
IL283267B (en) 2022-12-01
CA3024180A1 (en) 2017-12-14
HRP20201771T1 (hr) 2021-02-19
KR20220123727A (ko) 2022-09-08
IL263586A (en) 2019-01-31
RU2019100040A (ru) 2020-07-13
MX2021003939A (es) 2021-05-27
US20230174541A1 (en) 2023-06-08
EP3468966A1 (en) 2019-04-17
MX2023002982A (es) 2023-04-10
SI3468966T1 (sl) 2021-03-31
US20190144459A1 (en) 2019-05-16
US11479557B2 (en) 2022-10-25
IL283267A (en) 2021-07-29
MX2018015252A (es) 2019-04-25

Similar Documents

Publication Publication Date Title
MX381228B (es) Inhibidores de la interacción de menina-leucemia de linaje mixto.
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
BR112018012707A2 (pt) inibidores da interação de menin-mll
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
UY36075A (es) Derivados de tubulisina
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2018002368A1 (es) Formulaciones de oritavancina
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
AR100204A1 (es) Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye